TN2009000190A1 - Lingo binding molecules and pharmaceutical use thereof - Google Patents

Lingo binding molecules and pharmaceutical use thereof

Info

Publication number: TN2009000190A1
Authority: TN; Tunisia
Prior art keywords: binding molecule; binding molecules; pharmaceutical use; polynucleotide; treatment
Prior art date: 2006-11-17

Application number

TNP2009000190A

Other languages

English (en)

Inventor

Adrien Walmsley

William Leonard Wishart

Marta Cortes-Cros

Josef Prassler

Ingo Klagge

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-11-17

Filing date

2009-05-15

Publication date

2010-10-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38325542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000190(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-05-15 Application filed by Novartis Ag filed Critical Novartis Ag

2010-10-18 Publication of TN2009000190A1 publication Critical patent/TN2009000190A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Ophthalmology & Optometry (AREA)
Physical Education & Sports Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

TNP2009000190A 2006-11-17 2009-05-15 Lingo binding molecules and pharmaceutical use thereof TN2009000190A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06124350		2006-11-17
PCT/EP2007/009880 WO2008058736A1 (fr)	2006-11-17	2007-11-15	Molécules de liaison à lingo et utilisation pharmaceutique de celles-ci

Publications (1)

Publication Number	Publication Date
TN2009000190A1 true TN2009000190A1 (en)	2010-10-18

Family

ID=38325542

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000190A TN2009000190A1 (en)	2006-11-17	2009-05-15	Lingo binding molecules and pharmaceutical use thereof

Country Status (27)

Country	Link
US (4)	US8299221B2 (fr)
EP (2)	EP2084190B1 (fr)
JP (2)	JP5647414B2 (fr)
KR (1)	KR20090078353A (fr)
CN (2)	CN103351437A (fr)
AR (1)	AR063829A1 (fr)
AT (1)	ATE502960T1 (fr)
AU (1)	AU2007321817A1 (fr)
BR (1)	BRPI0718406A2 (fr)
CA (1)	CA2669181A1 (fr)
CL (1)	CL2007003303A1 (fr)
CO (1)	CO6180433A2 (fr)
CR (1)	CR10756A (fr)
DE (1)	DE602007013445D1 (fr)
EC (1)	ECSP099332A (fr)
ES (1)	ES2363622T3 (fr)
GT (1)	GT200900121A (fr)
IL (1)	IL198313A0 (fr)
MA (1)	MA30965B1 (fr)
MX (1)	MX2009005175A (fr)
NO (1)	NO20092331L (fr)
PE (1)	PE20081392A1 (fr)
RU (1)	RU2009122514A (fr)
TN (1)	TN2009000190A1 (fr)
TW (1)	TW200831534A (fr)
WO (1)	WO2008058736A1 (fr)
ZA (1)	ZA200902409B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE602004028916D1 (de)	2003-03-19	2010-10-14	Biogen Idec Inc	Nogo rezeptor bindendes protein
DK1776136T3 (da)	2004-06-24	2012-12-03	Biogen Idec Inc	Behandling af tilstande, der involverer demyelinisering
SG10201508322SA (en)	2005-07-08	2015-11-27	Biogen Ma Inc	Sp35 antibodies and uses thereof
US20090175872A1 (en) *	2005-12-02	2009-07-09	Biogen Idec Ma Inc.	Treatment of Conditions Involving Demyelination
EP2068866A4 (fr)	2006-07-24	2010-04-07	Biogen Idec Inc	Procedes pour favoriser la myelinisation, la survie neuronale et la differenciation des oligodendrocytes par administration d'antagonistes de sp35 ou trka
US8128926B2 (en)	2007-01-09	2012-03-06	Biogen Idec Ma Inc.	Sp35 antibodies and uses thereof
US20100297121A1 (en) *	2007-10-11	2010-11-25	Biogen Idec Ma Inc.	Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of LINGO-1 Antagonists and TrkB Agonists
AU2008325107B2 (en) *	2007-11-08	2015-04-23	Biogen Ma Inc.	Use of LINGO-4 antagonists in the treatment of conditions involving demyelination
EP2315779A2 (fr)	2008-07-09	2011-05-04	Biogen Idec MA Inc.	Compositions comprenant des anticorps anti-lingo ou leurs fragments
WO2011139714A2 (fr)	2010-04-26	2011-11-10	Atyr Pharma, Inc.	Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps se rapportant à des fragments protéiques de la cystéinyl-arnt synthétase
CA2797362C (fr)	2010-04-27	2020-12-08	Atyr Pharma, Inc.	Decouverte innovante de compositions therapeutiques, de diagnostic et d'anticorps se rapportant a des fragments proteiques d'isoleucyl arnt synthetases
CA2797259C (fr)	2010-04-27	2020-09-29	Atyr Pharma, Inc.	Decouverte innovante de compositions therapeutiques, de diagnostic et d'anticorps se rapportant a des fragments proteiques de threonyl arnt synthetases
AU2011248489B2 (en)	2010-04-28	2016-10-06	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases
CA2797374C (fr)	2010-04-29	2021-02-16	Pangu Biopharma Limited	Decouverte innovante de compositions therapeutiques, diagnostiques et a based' anticorps associees a des fragments proteiques d'asparaginyl-arnt-synthetases
JP5991963B2 (ja)	2010-04-29	2016-09-14	エータイアーファーマ，インコーポレイテッド	バリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2011140132A2 (fr)	2010-05-03	2011-11-10	Atyr Pharma, Inc.	Découverte innovante de compositions thérapeutiques, diagnostiques et à base d'anticorps liées à des fragments protéiques de phénylalanyl-alpha-arnt-synthétases
CN103096925A (zh)	2010-05-03	2013-05-08	Atyr医药公司	与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
JP6008841B2 (ja)	2010-05-03	2016-10-19	エータイアーファーマ，インコーポレイテッド	メチオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
AU2011248357B2 (en)	2010-05-03	2017-02-23	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases
WO2011140266A2 (fr)	2010-05-04	2011-11-10	Atyr Pharma, Inc.	Découverte innovante de compositions thérapeutiques, diagnostiques et à base d'anticorps liées à des fragments protéiques de glutamyl-prolyl-arnt-synthétases
WO2011140267A2 (fr)	2010-05-04	2011-11-10	Atyr Pharma, Inc.	Découverte innovante de compositions thérapeutiques, diagnostiques et à base d'anticorps liées à des fragments protéiques de complexe multi-arnt synthétase p38
CA2799197C (fr)	2010-05-14	2019-10-29	Atyr Pharma, Inc.	Decouverte de compositions inedites de nature therapeutique, diagnostique et a base d'anticorps contenant des fragments proteiques de phenylalanyl-beta-arnt synthetases
CA2799480C (fr)	2010-05-17	2020-12-15	Atyr Pharma, Inc.	Decouverte innovante de compositions therapeutiques, de diagnostic, et d'anticorps associees a des fragments proteiques de leucyl-arnt synthetases
EP2575856B1 (fr)	2010-05-27	2017-08-16	aTyr Pharma, Inc.	Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps liées à fragments protéiques de glutaminyl-arnt synthétases
EP2575857B1 (fr)	2010-06-01	2018-01-24	aTyr Pharma, Inc.	Découverte innovante de compositions thérapeutiques, diagnostiques, et d'anticorps associés à des fragments de protéine de lysyl-tarn synthétases
CA2804416C (fr)	2010-07-12	2020-04-28	Atyr Pharma, Inc.	Decouverte innovante de compositions therapeutiques, de diagnostic et d'anticorps se rapportant a des fragments proteiques de glycyl-arnt synthetases
EP2593124B1 (fr)	2010-07-12	2017-04-26	aTyr Pharma, Inc.	Découverte innovante de compositions thérapeutiques, diagnostiques et d'anticorps relatives à des fragments protéiques d'aspartyl-arnt synthétases
AU2011289833C1 (en)	2010-07-12	2017-06-15	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Histidyl-tRNA synthetases
US8999321B2 (en)	2010-07-12	2015-04-07	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
WO2012027611A2 (fr)	2010-08-25	2012-03-01	Atyr Pharma, Inc.	Découverte innovante de compositions thérapeutiques, diagnostiques et d'anticorps associées à des fragments protéiniques des tyrosyl-arnt synthétases
JP6039566B2 (ja)	2010-10-06	2016-12-07	エータイアーファーマ，インコーポレイテッド	治療用、診断用および抗体組成物に関連したトリプトファニルｔＲＮＡ合成酵素のタンパク質フラグメントの革新的発見
US9714419B2 (en)	2011-08-09	2017-07-25	Atyr Pharma, Inc.	PEGylated tyrosyl-tRNA synthetase polypeptides
US9822353B2 (en)	2011-12-06	2017-11-21	Atyr Pharma, Inc.	PEGylated aspartyl-tRNA synthetase polypeptides
US9816084B2 (en)	2011-12-06	2017-11-14	Atyr Pharma, Inc.	Aspartyl-tRNA synthetases
WO2013115926A2 (fr)	2011-12-29	2013-08-08	Atyr Pharma, Inc.	Conjugués aspartyl-arnt synthétase-fc
EP2806948B1 (fr)	2012-01-27	2020-01-15	New York University	Méthode d'amélioration de la remyélinisation à l'aide d'inhibiteurs gli1
CA2873623C (fr) *	2012-05-14	2021-11-09	Biogen Idec Ma Inc.	Antagonistes de lingo-2 pour le traitement d'affections impliquant des neurones moteurs
ES2708565T3 (es)	2013-03-15	2019-04-10	Atyr Pharma Inc	Conjugados de Fc-histidil-ARNt sintetasa
AU2016205197B2 (en)	2015-01-08	2021-10-21	Biogen Ma Inc.	LINGO-1 antagonists and uses for treatment of demyelinating disorders
EP3251235B1 (fr) *	2015-01-26	2021-03-24	Apple Inc.	Dispositif et procédé pour améliorer la précision de positionnement horizontal et vertical
AU2017297404A1 (en) *	2016-07-13	2019-01-24	Biogen Ma Inc.	Dosage regimens of LINGO-1 antagonists and uses for treatment of demyelinating disorders
JP7679175B2 (ja)	2017-04-20	2025-05-19	エータイアーファーマ，インコーポレイテッド	肺の炎症を治療するための組成物および方法
KR102414826B1 (ko)	2020-06-18	2022-06-30	삼성전기주식회사	코일 부품

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308573D0 (en)	1983-03-29	1983-05-05	British Nuclear Fuels Ltd	Filament impregnating/coating
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
WO1988001649A1 (fr)	1986-09-02	1988-03-10	Genex Corporation	Molecules de liaison de chaines de polypeptide simples
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
HU217219B (hu)	1989-02-13	1999-12-28	Schering Ag. Berlin Und Bergkamen	Trombolitikus hatású fehérjék, ezeket kódoló izolált DNS, ilyen DNS-sel transzformált vektorokat tartalmazó mikroorganizmusok, és eljárás a trombolitikus hatású fehérjék előállítására
CN1798840B (zh) *	2003-03-19	2010-11-10	比奥根艾迪克Ma公司	Nogo受体结合蛋白
DE602004028916D1 (de) *	2003-03-19	2010-10-14	Biogen Idec Inc	Nogo rezeptor bindendes protein
US20050214288A1 (en)	2004-03-26	2005-09-29	Human Genome Sciences, Inc.	Antibodies against Nogo receptor
DK1776136T3 (da) *	2004-06-24	2012-12-03	Biogen Idec Inc	Behandling af tilstande, der involverer demyelinisering
SG10201508322SA (en)	2005-07-08	2015-11-27	Biogen Ma Inc	Sp35 antibodies and uses thereof

2007
- 2007-11-15 CN CN2013102559773A patent/CN103351437A/zh active Pending
- 2007-11-15 PE PE2007001587A patent/PE20081392A1/es not_active Application Discontinuation
- 2007-11-15 CN CN2007800415830A patent/CN101553506B/zh not_active Expired - Fee Related
- 2007-11-15 RU RU2009122514/10A patent/RU2009122514A/ru not_active Application Discontinuation
- 2007-11-15 CA CA002669181A patent/CA2669181A1/fr not_active Abandoned
- 2007-11-15 AR ARP070105078A patent/AR063829A1/es not_active Application Discontinuation
- 2007-11-15 US US12/514,542 patent/US8299221B2/en not_active Expired - Fee Related
- 2007-11-15 MX MX2009005175A patent/MX2009005175A/es not_active Application Discontinuation
- 2007-11-15 EP EP07846601A patent/EP2084190B1/fr not_active Revoked
- 2007-11-15 KR KR1020097009952A patent/KR20090078353A/ko not_active Ceased
- 2007-11-15 BR BRPI0718406-9A patent/BRPI0718406A2/pt not_active IP Right Cessation
- 2007-11-15 AU AU2007321817A patent/AU2007321817A1/en not_active Abandoned
- 2007-11-15 DE DE602007013445T patent/DE602007013445D1/de active Active
- 2007-11-15 AT AT07846601T patent/ATE502960T1/de not_active IP Right Cessation
- 2007-11-15 EP EP11151300A patent/EP2395022A1/fr not_active Withdrawn
- 2007-11-15 JP JP2009536654A patent/JP5647414B2/ja not_active Expired - Fee Related
- 2007-11-15 ES ES07846601T patent/ES2363622T3/es active Active
- 2007-11-15 WO PCT/EP2007/009880 patent/WO2008058736A1/fr not_active Ceased
- 2007-11-16 CL CL200703303A patent/CL2007003303A1/es unknown
- 2007-11-16 TW TW096143597A patent/TW200831534A/zh unknown
2009
- 2009-04-07 ZA ZA200902409A patent/ZA200902409B/xx unknown
- 2009-04-23 IL IL198313A patent/IL198313A0/en unknown
- 2009-04-29 CR CR10756A patent/CR10756A/es not_active Application Discontinuation
- 2009-05-12 GT GT200900121A patent/GT200900121A/es unknown
- 2009-05-12 CO CO09048055A patent/CO6180433A2/es not_active Application Discontinuation
- 2009-05-15 TN TNP2009000190A patent/TN2009000190A1/fr unknown
- 2009-05-15 EC EC2009009332A patent/ECSP099332A/es unknown
- 2009-06-03 MA MA31944A patent/MA30965B1/fr unknown
- 2009-06-17 NO NO20092331A patent/NO20092331L/no not_active Application Discontinuation
2012
- 2012-09-14 US US13/616,226 patent/US20130071400A1/en not_active Abandoned
- 2012-10-04 JP JP2012222370A patent/JP2013056888A/ja active Pending
2013
- 2013-09-26 US US14/037,841 patent/US20140037639A1/en not_active Abandoned
2014
- 2014-05-19 US US14/280,933 patent/US20140255415A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2084190B1 (fr)	2011-03-23
ECSP099332A (es)	2009-06-30
US20140255415A1 (en)	2014-09-11
JP2010509906A (ja)	2010-04-02
PE20081392A1 (es)	2008-11-12
ATE502960T1 (de)	2011-04-15
KR20090078353A (ko)	2009-07-17
MA30965B1 (fr)	2009-12-01
CN103351437A (zh)	2013-10-16
US20140037639A1 (en)	2014-02-06
DE602007013445D1 (de)	2011-05-05
EP2395022A1 (fr)	2011-12-14
CA2669181A1 (fr)	2008-05-22
TW200831534A (en)	2008-08-01
AR063829A1 (es)	2009-02-18
US20100143362A1 (en)	2010-06-10
ES2363622T3 (es)	2011-08-10
IL198313A0 (en)	2011-08-01
WO2008058736A1 (fr)	2008-05-22
US8299221B2 (en)	2012-10-30
CR10756A (es)	2009-06-04
EP2084190A1 (fr)	2009-08-05
AU2007321817A1 (en)	2008-05-22
CL2007003303A1 (es)	2008-06-27
NO20092331L (no)	2009-06-17
US20130071400A1 (en)	2013-03-21
MX2009005175A (es)	2009-08-07
CN101553506B (zh)	2013-08-07
EP2395022A9 (fr)	2013-04-24
BRPI0718406A2 (pt)	2013-12-17
RU2009122514A (ru)	2010-12-27
GT200900121A (es)	2011-11-11
JP5647414B2 (ja)	2014-12-24
JP2013056888A (ja)	2013-03-28
ZA200902409B (en)	2010-04-28
CO6180433A2 (es)	2010-07-19
CN101553506A (zh)	2009-10-07

Publication	Publication Date	Title
TN2009000190A1 (en)	2010-10-18	Lingo binding molecules and pharmaceutical use thereof
MX2009012650A (es)	2010-02-18	Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
UA100682C2 (ru)	2013-01-25	АНТИТЕЛО, КОТОРОЕ НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ ЦИТОМЕГАЛОВИРУС (hCMV), И ЕГО ПРИМЕНЕНИЕ
NZ603570A (en)	2014-12-24	Biological materials related to her3
MX2009010610A (es)	2010-06-08	Dominio de enlace especifico de especies cruzadas.
IL187321A0 (en)	2008-04-13	Host cell specific binding molecules capable of neutralizing viruses and uses thereof
BRPI0511479A (pt)	2007-12-26	molécula de ligação tendo atividade neutralizadora do vìrus da raiva, variante funcional de uma molécula de ligação, imunoconjugado, molécula de ácido nucléico, vetor, hospedeiro, método para produzir uma molécula de ligação ou uma variante funcional, composição farmacêutica, uso de uma molécula de ligação, uma variante funcional, um imunoconjugado como, ou uma composição, kit, método para identificar uma molécula de ligação ou uma molécula de ácido nucléico, e, coleção de moléculas de ligação humanas na superfìcie de pacotes genéticos replicáveis
WO2008065372A3 (fr)	2008-10-23	Polypeptides d'érythropoïétine modifiés et utilisation de ceux-ci dans des traitements
MX2009002816A (es)	2009-05-28	Proteinas de fusion de albumina.
BRPI0809594A2 (pt)	2019-08-27	polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s)
CA2818969A1 (fr)	2012-05-31	Modules de coiffage n-terminal ameliores pour des proteines de repetitions d'ankyrine concues
MX2009001203A (es)	2009-06-01	Muteinas de lipocalina lacrimosa y metodos para obtener las mismas.
WO2008077945A3 (fr)	2008-11-27	Séquences d'acides aminés dirigées contre des chimiokines et polypeptides comprenant celles-ci pour le traitement de maladies et de troubles liés aux chimiokines
MX2008009886A (es)	2008-10-23	Anticuerpos que enlazan par-2.
ATE541283T1 (de)	2012-01-15	Verfahren zum mischen von farben in einem display
WO2007054520A3 (fr)	2007-08-09	Procedes d'identification du microarn et leurs applications en termes de recherche et de sante humaine
WO2009152480A3 (fr)	2010-06-17	Procédés de traitement des tumeurs solides
SI2010563T1 (sl)	2011-07-29	Sintetična MeCP2 sekvenca za proteinsko nadomestno terapijo
WO2010011994A3 (fr)	2010-04-29	Polypeptides et leurs utilisations
TN2010000199A1 (en)	2011-11-11	Improved nogo-a binding molecules and pharmaceutical use thereof
SG146660A1 (en)	2008-10-30	Nogo-a binding molecules and pharmaceutical uses thereof
WO2005121328A3 (fr)	2006-04-06	Methode permettant d'ameliorer un etat inflammatoire de la peau
WO2010036031A3 (fr)	2010-06-24	Anticorps monoclonal humain specifique au pauf, composition pharmaceutique destinee au traitement du cancer le comprenant et procede l'utilisant pour detecter le cancer
WO2010065536A3 (fr)	2010-09-16	Antigène-2 du stroma de la moelle osseuse recombinant dans le traitement de maladies auto-immunes
TW200724679A (en)	2007-07-01	Treatment of disease using an improved regulated expression system